Civil Society Warns Thai-EU FTA Could Send Medicine Prices Soaring, Impacting Access for Thais
Thailand is currently in the process of negotiating a Free Trade Agreement (FTA) with the European Union (EU), which marks a significant step in expanding economic opportunities. However, civil society organizations and expert groups have expressed concerns regarding provisions in the "Intellectual Property" chapter, which could severely impact Thailand's public health system in the long term.
According to data from civil society, if Thailand accepts the intellectual property conditions proposed by the EU, it could result in the country's drug expenditures skyrocketing to 3.7 trillion baht. This staggering figure has caused significant concern among academics, as it would place a heavy burden on the government's public health budget and could affect the sustainability of the Universal Health Coverage system.
The increase in medicine prices would directly impact public access to treatments, particularly for chronic diseases or conditions requiring high-tech manufacturing. Furthermore, it could undermine the country's "pharmaceutical security," as the agreement might make it more difficult to produce affordable generic drugs domestically, forcing Thailand to rely primarily on imported medicines.
Consequently, various sectors are calling on the government and the negotiating team to consider this agreement carefully, prioritizing public interest and access to medical treatment. This negotiation represents a major challenge for Thailand in balancing trade benefits with the health security of its citizens.